Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $7.40 Consensus Price Target from Analysts

by · The Cerbat Gem

Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $7.40.

Several equities analysts have commented on the company. Stephens reiterated an “overweight” rating and set a $5.00 price target on shares of Actinium Pharmaceuticals in a report on Tuesday, November 19th. StockNews.com lowered shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Actinium Pharmaceuticals in a research report on Friday, November 15th.

Get Our Latest Analysis on ATNM

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Rhumbline Advisers raised its stake in Actinium Pharmaceuticals by 23.4% during the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after acquiring an additional 7,525 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Actinium Pharmaceuticals in the 2nd quarter valued at about $92,000. Bank of New York Mellon Corp lifted its holdings in Actinium Pharmaceuticals by 28.3% in the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after buying an additional 19,035 shares during the period. Renaissance Technologies LLC bought a new position in Actinium Pharmaceuticals in the second quarter valued at approximately $142,000. Finally, Interchange Capital Partners LLC acquired a new stake in Actinium Pharmaceuticals during the 3rd quarter worth $37,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Stock Performance

ATNM opened at $1.39 on Wednesday. The company has a market cap of $43.36 million, a P/E ratio of -1.00 and a beta of 0.12. The business’s 50-day moving average is $1.44. Actinium Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $10.24.

Actinium Pharmaceuticals Company Profile

(Get Free Report

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).

Further Reading